Dr. Reddy’s Laboratories Ltd. has confirmed that a news item published on November 3, 2026, regarding a U.S. FDA tentative approval for a generic HIV prevention shot is correct. The company’s press release from November 2, 2026, titled “U.S. FDA grants tentative approval for Dr. Reddy’s twice-yearly injectable lenacapavir, advancing access to HIV prevention across 120 countries outside the US,” accurately reflects this development. This approval aims to enhance access to HIV prevention in numerous countries.
Dr. Reddy’s Confirms HIV Prevention Shot Approval
Dr. Reddy’s Laboratories Ltd. has issued a clarification regarding a news article published on November 3, 2026. The company confirmed the accuracy of the headline, which stated that Dr. Reddy’s had received U.S. FDA approval for a generic HIV prevention shot. This development is a significant step towards increasing access to critical health solutions globally.
Details of the Approval
The news pertains to the company’s press release dated November 2, 2026, titled, “U.S. FDA grants tentative approval for Dr. Reddy’s twice-yearly injectable lenacapavir, advancing access to HIV prevention across 120 countries outside the US.” This tentative approval signifies a major advancement in making HIV prevention more accessible, particularly in 120 countries outside the United States. The medication is a twice-yearly injectable formulation.
Regulatory Disclosure
Dr. Reddy’s Laboratories stated that this matter does not constitute a material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulations. The company affirmed its commitment to making timely disclosures of all material events and information as required by the regulations.
Source: BSE
